LGDN Stock Chart & Stats
€236.00
-€2.00(-0.77%)
At close: 4:00 PM EDT
€236.00
-€2.00(-0.77%)
Day’s Range― - ―
52-Week Range€140.00 - €280.00
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€4.93B
Enterprise Value€6.68K
Total Cash (Recent Filing)€1.36B
Total Debt (Recent Filing)€1.13B
Price to Earnings (P/E)29.0
Beta0.35
Next Earnings
Nov 05, 2026EPS Estimate
1.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.01
Shares Outstanding19,935,610
10 Day Avg. Volume2
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€306.06Price Target Upside29.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)8
Revenue Forecast (FY)€250.33M
Bulls Say, Bears Say
Bulls Say
Royalty Revenue GrowthGrowth in partner products supports Ligand’s asset-light royalty model, allowing revenue and margins to scale without carrying the cost of direct commercialization. Expanding partner sales can provide recurring economics over multiple years.
Expanded Royalty PortfolioThe XOMA acquisition materially broadens Ligand’s commercial and development portfolio, diversifies dependence on individual products, and extends potential royalty duration. More late-stage assets also create multiple paths to future milestone and royalty growth.
Strong Cash GenerationExpected operating cash flow gives Ligand internal funding for acquisitions, partnerships and corporate needs while reducing reliance on external capital. Strong cash conversion also supports the scalability of its partner-centric royalty model.
Bears Say
Higher Financial LeverageThe higher debt burden reduces balance-sheet flexibility and increases financial risk if royalty receipts or milestone income weaken. It may also constrain future acquisitions or raise financing dependence while Ligand integrates XOMA.
Uneven Cash-flow HistoryRecent cash generation is encouraging, but prior swings show that milestone timing, partner activity and portfolio events can make cash conversion inconsistent. This limits confidence that current cash-flow strength will persist evenly across periods.
Clinical And Regulatory Timing RiskAdditional clinical requirements delay potential approval, milestones and royalties from volixibat. More broadly, Ligand’s reliance on partner development means regulatory setbacks can defer or eliminate expected economics despite portfolio diversification.
Ligand Pharma News
LGDN FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was €140.00 and its highest was €280.00 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is €4.93B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 44 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Aug 06, 2026. The company reported €2.047 earnings per share for the quarter, beating the consensus estimate of €1.736 by €0.311.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma does not currently pay dividends.
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.99.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,935,610 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of €2.047 in its last earnings report, beating expectations of €1.736. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in DE:LGDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€306.06 (29.69% Upside)
€306.06 (29.69% Upside)
Blogger Sentiment
Neutral
DE:LGDN Sentiment 50%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth €2.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
130.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGDN Company Deck
LGDN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum: robust top-line and EPS growth, significant cash flow generation, completion of an accretive and scalable acquisition (XOMA), and successful low-cost financing that materially strengthens capital flexibility. Manageable near-term challenges include a product sales decline (Kyprolis), one-time charges, accounting complexity from increased financial royalty assets, and some timing risk from an FDA recommendation requiring a Phase III for PSC. On balance, the company presented multiple clear growth drivers and disciplined capital deployment that outweigh the identified risks.View all DE:LGDN earnings summariesLGDN Stock 12 Month Forecast
Average Price Target
€306.06
▲(29.69% Upside)